END OF SUMMER SALE - 50% Off Site Wide•END OF SUMMER SALE - 50% Off Site Wide•END OF SUMMER SALE - 50% Off Site Wide•END OF SUMMER SALE - 50% Off Site Wide•END OF SUMMER SALE - 50% Off Site Wide•END OF SUMMER SALE - 50% Off Site Wide•END OF SUMMER SALE - 50% Off Site Wide•END OF SUMMER SALE - 50% Off Site Wide•
END OF SUMMER SALE - 50% Off Site Wide•END OF SUMMER SALE - 50% Off Site Wide•END OF SUMMER SALE - 50% Off Site Wide•END OF SUMMER SALE - 50% Off Site Wide•END OF SUMMER SALE - 50% Off Site Wide•END OF SUMMER SALE - 50% Off Site Wide•END OF SUMMER SALE - 50% Off Site Wide•END OF SUMMER SALE - 50% Off Site Wide•
1 / 6
Verified Lab Results
Finished in the USA
Research Use Only
Recommended with this order
Frequently paired with this compound by other researchers.
Mix and match vials, capsules, sprays and serums. The more you add, the more you save.
Build Your PackAdd products and your discount is applied automatically.Build Your Pack →
RUO
For Research Use Only. Not for human consumption or therapeutic treatment.
99% Pure | Multi Dose | Finished in the USA
ARA-290 (Cibinetide) is an 11-amino-acid synthetic peptide derived from erythropoietin that selectively activates the innate repair receptor (IRR) without stimulating red-blood-cell production. Widely used in preclinical models of neuroinflammation, organ protection, and metabolic regulation, ARA-290 offers precise IRR engagement and robust cytoprotective signaling. Each 16 mg vial is verified at ≥99% purity by HPLC, screened for endotoxin (<0.1 EU/mg), and delivered with a full Certificate of Analysis.
Do not use regular BAC water with ARA-290.
It can become cloudy or gel-like when reconstituted with bacteriostatic water (BAC) due to its hydrophobic nature and lower solubility.
Using phosphate-buffered saline (PBS) instead of BAC is often recommended to improve solubility and prevent these issues.
What Is ARA-290?
ARA-290, also known as Cibinetide, is a lab-engineered 11-amino-acid peptide fragment of erythropoietin that selectively engages the innate repair receptor (IRR). Unlike full-length EPO, ARA-290 triggers cytoprotective and anti-inflammatory pathways without stimulating erythropoiesis. In preclinical research, it’s applied to neural, cardiovascular, renal, and metabolic models to explore mechanisms of tissue protection, inflammation modulation, and cell-survival signaling.
Why Choose ARA-290?
Researchers choose ARA-290 for its unmatched selectivity: it binds the IRR to activate PI3K/Akt and STAT3 pathways that promote cell survival, reduce inflammatory damage, and enhance tissue repair. Its small size ensures rapid tissue penetration and consistent receptor engagement. Each vial is produced under, cGMP-like standards and validated by HPLC (>99% purity), MS/MS sequence confirmation, and endotoxin testing—guaranteeing reproducible results across neural, cardiac, and metabolic study designs.
What Sets ARA-290 Apart?
Unlike broader cytokine-mimetic peptides, ARA-290 isolates the reparative arm of EPO signaling via the IRR, without engaging hematopoietic signaling. This targeted action enables clear investigation of cytoprotection in models of ischemia, neurodegeneration, and metabolic stress. Coupled with its demonstrated stability in both lyophilized and reconstituted forms, ARA-290 stands out as a precision tool for dissecting IRR-mediated tissue-repair and anti-inflammatory mechanisms.
